Trupanion (TRUP)

Nasdaq Financials Life & Health Insurance S&P SmallCap 600
$36.75
+2.03 (+5.85%)
Close of Nov 06, 2026 · end-of-day data
SMA 50SMA 2005Y/10Y use weekly candles (10/40-week averages)

Performance

price return
1W+22.0%
1M+42.3%
3M+26.5%
6M+49.3%
YTD-1.7%
1Y-13.5%
3Y+79.6%
5Y-64.1%

Key statistics

Full financials →
Market cap$1.6B
P/E (TTM)60.2
EPS (TTM, diluted)$0.61
P/S1.02
P/B3.98
EV / EBITDA35.4
Revenue (TTM)$1.56B
Revenue growth+11.4%
Net margin1.7%
ROE6.7%
Debt / equity0.26
FCF yield5.5%
Dividend yield—
Payout ratio—
Beta (1Y)0.02
Volatility (1Y)48.3%
52-week range$21.16 – $46.98
Avg volume (50D)440.77K

Revenue & net income — last 8 quarters

Statements →
Nov 5, 4:02 PM ET

Trupanion Q3 2026 revenue rose 11% to $405.6 million; net income $9.3 million

Positive earnings 2.02

Trupanion reported third-quarter 2026 results for the period ended September 30, 2026. Total revenue rose 11% to $405.6 million, net income was $9.3 million, or $0.21 per diluted share, compared with $5.9 million, or $0.13 per diluted share, a year earlier. The company also repurchased about $25.0 million of its stock in the quarter, leaving about $75.0 million available under its $100.0 million buyback program.

  • Total revenue was $405.6 million, up 11% from $366.9 million in Q3 2025.
  • Net income was $9.3 million, or $0.21 per diluted share, versus $5.9 million, or $0.13 per diluted share, in Q3 2025.
  • Adjusted EBITDA was $20.8 million, compared with $19.6 million in Q3 2025.
  • Operating cash flow was $30.7 million and free cash flow was $28.5 million in Q3 2026; about $25.0 million of stock was repurchased in the quarter.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Recent SEC filings

EDGAR ↗

Famous investors who own TRUP

All investors →
InvestorValue% of portfolioLast quarter
Renaissance Technologies $1.17M0.00% Added

From each investor's latest 13F filing (Q2 2026); positions are as of the quarter end and filed up to 45 days later.

Insider transactions

All insider trades →
DateInsiderTypeSharesPriceValue
Oct 28Gallagher John R
Chief Operating Officer
Sell 10b5-1431$29.12$12.55K
Oct 09Tooth Margaret
Director, CEO
Sell 10b5-11.00K$25.84$25.84K
Sep 28Gallagher John R
Chief Operating Officer
Sell 10b5-1431$22.92$9.88K

Prices are end-of-day and split-adjusted. Financial data from Trupanion's SEC XBRL filings. Not investment advice.